Anti-PAI-1 Mouse mAb (7)

Plasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.

Purified mouse monoclonal antibody. Recognizes the latent form of the ~50 kDa PAI-1 protein.

Recognizes the latent form of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.

This Anti-PAI-1 Mouse mAb (7) is validated for use in Immunoblotting, Immunoprecipitation for the detection of PAI-1.

partially purified human PAI-1 from conditioned medium of dexamethasone-treated HT1080 cells

Immunoblotting (1 μg/ml)
Immunoprecipitation (see applications refrences)

Lyophilized from a volatile buffer, 100 μg BSA.

We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Lyophilized antibodies shou

Positive Control
Conditioned media from dexamethasone-treated HT-1080 cells

PAI (Ab-3) will detect latent but not active PAI-1. Antibody should be titrated for optimal results in individual systems.

Sold under license of U.S. Patent 5,422,245.